Trially Co-founder and CEO Kyle McAllister, explains how AI absorbing the bulk of clinical-trial chart reviews can free research sites to focus staff time on higher-value tasks.
News|Podcasts|August 24, 2026
ACT Brief: AI Literacy and Ecosystem Adoption Requirements, CRO Operating Models Under Agentic AI Pressure, and Platform Collaborations in Vaccine and Antibody Discovery
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine the three conditions required for AI-driven trial acceleration to work at scale, why agentic AI will force CRO operating model reckoning, and two major platform collaborations advancing discovery speed.
Advertisement
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In
part five and final segment of her interview , Amber Hill, PhD, founder and CEO of Research Grid, outlines the three conditions required for AI-driven trial acceleration to work at scale: broad AI literacy, shared boundaries around where it can be applied safely, and incremental adoption of purpose-built tools across the entire ecosystem. Without these preconditions, AI tools remain siloed enablers rather than systemic accelerators. - In a
new contributed article , Joanna Williams, chief operating officer of Mintra Health, examined how agentic AI will put the CRO operating model to the test by removing organizational slack and forcing efficiency and accountability questions the industry can no longer avoid. When processes run efficiently end-to-end, structural failures in sponsorship, oversight, and partnering become immediately visible. Eli Lilly partnered with Amplitude Therapeutics to develop RNA vaccines for infectious diseases , with Lilly holding exclusive target-specific commercialization rights while Amplitude leads optimization and preclinical work. Separately, Bristol Myers Squibb entered a collaboration with Chai Discovery to deploy AI molecular folding and design models across BMS's antibody discovery portfolio to accelerate the timeline from target identification to viable candidates.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Advertisement
Related to this article
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, explains why the shift from narrow AI tools to a continuous learning clinical operating system is where the real operational value lies—and what it takes to get there.
In this Q&A, Saamir Pasha and Carole Berini, PhD, of Ontada discuss what it takes to harmonize fragmented oncology data into reliable real-world evidence, how lab markers can proxy for missing functional status data, and where the biggest remaining barriers to consistent RWE generation lie.
In today’s ACT Brief, we examine who decides what trials measure, how designing for human thinking improves site execution, and how the FDA extended an immunotherapy to a new bladder cancer population.
Clinical trial endpoints define what success looks like, but patients and caregivers are rarely the ones setting that definition, and the gap between what trials measure and what patients actually value is showing up in post-approval evidence, regulatory submissions, and the design rooms where protocols are written.
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.
In today’s ACT Brief, we examine what it will take to scale EHR-to-EDC connections for real-time trials, how the FDA is reimagining rare disease drug development, and why oncology real-world evidence still faces persistent data barriers.
A new white paper and public engagement process outline the FDA’s commitment to building fit-for-purpose evidentiary standards, stronger patient voice integration, and greater regulatory predictability across rare disease drug development and review.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Real-Time Clinical Trials Depend on a Scalable EHR-to-EDC Connection
2
FDA Launches Rare Disease Framework Initiative to Reimagine Drug Development for Small Patient Populations
3
The Human Side of Clinical Trials: Why Fuzzy Mental Models Undermine Clinical Trial Execution
4
What It Actually Means to Embed AI Across the Clinical Operating Model
5